110 results
8-K
EX-99.1
SAGE
Sage Therapeutics Inc
25 Apr 24
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
6:46am
. The reimbursement from Biogen to Sage for R&D expenses pursuant to the Sage/Biogen Collaboration and License Agreement was $5.7 million in the first quarter … restructuring. The reimbursement from Sage to Biogen for SG&A expenses pursuant to the Sage/Biogen Collaboration and License Agreement was $2.3 million
8-K
EX-99.1
7n7cqf6
14 Feb 24
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
6:45am
8-K
EX-99.2
9jjtsi6 0viurqgrsd
8 Jan 24
Departure of Directors or Certain Officers
6:45am
8-K
EX-1.1
f8bckam zsys
7 Nov 23
Entry into a Material Definitive Agreement
7:39am
8-K
EX-99.1
qob304rujo qg9luicbz
7 Nov 23
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
6:46am
8-K
EX-99.1
pbjt93r yr
7 Aug 23
Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
6:45am
8-K
EX-99.1
leiz0389ov2wy she
2 May 23
Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
6:45am